Other substances

Stenoparib

A PARP and tankyrase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Stenoparib is a poly (ADP-ribose) polymerase/tankyrase inhibitor clinically trialled for treatment of ovarian cancer. It manifests anti-coronaviral properties at the pre-entry and post-entry stages of infection in vitro (Stone et al., 2021).

Stenoparib on DrugBank
Stenoparib on PubChem

Synonyms

E7449; 2X-121; 8-((1,3-dihydro-2H-isoindol-2-yl)methyl)-1,2-dihydro-3H-Pyridazino(3,4,5-de)quinazolin-3-one

 

Structure image - Stenoparib

C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3

Supporting references

Link Tested on Impact factor Notes Publication date
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro
Small molecule In vitro 		Vero E6 cells; Calu-3 cells; SARS-CoV-2 (strain USA-WA1/2020) 6.78

Dose-dependently inhibits SARS-CoV-2 infection in vitro with EC50 of 25.5 μM. It has low cytotoxicity in Calu-3 cells (cytotoxic in Vero E6 at concentrations above 30 μM). At 10 μM, if combined with 0.5 μM remdesivir, >90% inhibition of viral replication is observed (a potential synergy between the drugs). Stenoparib likely acts at pre-entry or early post-entry stages of viral infection.

 Jan/19/2021
Export (.csv)